These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34825181)

  • 61. Applications of Reactive Cysteine Profiling.
    Backus KM
    Curr Top Microbiol Immunol; 2019; 420():375-417. PubMed ID: 30105421
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fragment-based covalent ligand discovery.
    Lu W; Kostic M; Zhang T; Che J; Patricelli MP; Jones LH; Chouchani ET; Gray NS
    RSC Chem Biol; 2021 Apr; 2(2):354-367. PubMed ID: 34458789
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
    Gehringer M; Laufer SA
    J Med Chem; 2019 Jun; 62(12):5673-5724. PubMed ID: 30565923
    [TBL] [Abstract][Full Text] [Related]  

  • 64. ABPP-CoDEL: Activity-Based Proteome Profiling-Guided Discovery of Tyrosine-Targeting Covalent Inhibitors from DNA-Encoded Libraries.
    Jiang L; Liu S; Jia X; Gong Q; Wen X; Lu W; Yang J; Wu X; Wang X; Suo Y; Li Y; Uesugi M; Qu ZB; Tan M; Lu X; Zhou L
    J Am Chem Soc; 2023 Nov; 145(46):25283-25292. PubMed ID: 37857329
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CovBinderInPDB: A Structure-Based Covalent Binder Database.
    Guo XK; Zhang Y
    J Chem Inf Model; 2022 Dec; 62(23):6057-6068. PubMed ID: 36453831
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Collapsin response mediator protein 2: high-resolution crystal structure sheds light on small-molecule binding, post-translational modifications, and conformational flexibility.
    Myllykoski M; Baumann A; Hensley K; Kursula P
    Amino Acids; 2017 Apr; 49(4):747-759. PubMed ID: 28044206
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Advances in the application of affinity separation for analyzing protein ubiquitination].
    Zhong H; Huang Y; Jin Y; Zhao R
    Se Pu; 2021 Jan; 39(1):26-33. PubMed ID: 34227356
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genie in a bottle: controlled release helps tame natural polypharmacology?
    Long MJ; Liu X; Aye Y
    Curr Opin Chem Biol; 2019 Aug; 51():48-56. PubMed ID: 30913473
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative Analysis of Pharmacophore Features and Quantitative Structure-Activity Relationships for CD38 Covalent and Non-covalent Inhibitors.
    Zhang S; Xue X; Zhang L; Zhang L; Liu Z
    Chem Biol Drug Des; 2015 Dec; 86(6):1411-24. PubMed ID: 26072680
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mechanism-Based and Computational-Driven Covalent Drug Design.
    Luo YL
    J Chem Inf Model; 2021 Nov; 61(11):5307-5311. PubMed ID: 34757749
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Achieving a low human dose for targeted covalent drugs: Pharmacokinetic and pharmacodynamic considerations on target characteristics and drug attributes.
    Yang Z
    Biopharm Drug Dispos; 2021 Apr; 42(4):150-159. PubMed ID: 33547681
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Statistical Analysis and Prediction of Covalent Ligand Targeted Cysteine Residues.
    Zhang W; Pei J; Lai L
    J Chem Inf Model; 2017 Jun; 57(6):1453-1460. PubMed ID: 28510428
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Covalent inhibitors design and discovery.
    De Cesco S; Kurian J; Dufresne C; Mittermaier AK; Moitessier N
    Eur J Med Chem; 2017 Sep; 138():96-114. PubMed ID: 28651155
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeting RNA with small molecules-A safety perspective.
    Lightfoot HL; Smith GF
    Br J Pharmacol; 2023 Jan; ():. PubMed ID: 36631428
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery.
    Hallenbeck KK; Turner DM; Renslo AR; Arkin MR
    Curr Top Med Chem; 2017; 17(1):4-15. PubMed ID: 27449257
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Research progress of the small molecule covalent inhibitors].
    Yang B; Wang WJ; Li LL
    Yao Xue Xue Bao; 2014 Feb; 49(2):158-65. PubMed ID: 24761604
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Exploration of the Tunability of BRD4 Degradation by DCAF16
    Hassan MM; Li YD; Ma MW; Teng M; Byun WS; Puvar K; Lumpkin R; Sandoval B; Rutter JC; Jin CY; Wang MY; Xu S; Schmoker AM; Cheong H; Groendyke BJ; Qi J; Fischer ES; Ebert BL; Gray NS
    bioRxiv; 2023 Oct; ():. PubMed ID: 37873358
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
    Kiely-Collins H; Winter GE; Bernardes GJL
    Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.